Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06134986 · ClinicalTrials.gov registry record · NA
Intermittent Fasting in Adults With Type 1 Diabetes
A NA study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT06134986 is a NA study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 32 participants.
The verdict
NCT06134986, a NA study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The majority of adults with type 1 diabetes (T1DM) have either overweight or obesity. As such, dietary management has been recommended as an adjunct to insulin treatment to improve glycemic control and facilitate weight loss in patients with T1DM. Daily calorie restriction (CR) is the main diet prescribed to patients with T1DM for weight loss. However, many patients find it difficult to adhere to CR because calorie intake must be vigilantly monitored every day. In light of these problems with CR, another approach that limits timing of food intake, instead of number of calories consumed, has been developed. This diet is called "time restricted eating" (TRE) and involves confining the period of food intake to 6-8 h per day. TRE allows individuals to self-select foods and eat ad libitum during a large part of the day, which greatly increases compliance to these protocols. The simplicity of TRE, its accommodation of dietary preferences, and associated weight loss may translate to improved glycemic measures in patients with T1DM. The present study will be the first randomized controlled trial to compare the effect of TRE versus CR for weight management and improved glycemic control in adults with obesity and T1DM.
Interventions
- OTHER Time restricted eating
- OTHER Daily calorie restriction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2025-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06134986
The ClinicalTrials.gov registry entry for NCT06134986 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Time restricted eating is the first listed.
NCT06134986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06134986 about?
NCT06134986 is a clinical study titled "Intermittent Fasting in Adults With Type 1 Diabetes". The majority of adults with type 1 diabetes (T1DM) have either overweight or obesity. As such, dietary management has been recommended as an adjunct to insulin treatment to improve glycemic control and facilitate weight loss in patients with T1DM. Daily calorie restriction (CR) is the main diet pres...
What is the current status of trial NCT06134986?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2023-11-20. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT06134986?
The interventions under investigation include: Time restricted eating (OTHER), Daily calorie restriction (OTHER).
Who is sponsoring clinical trial NCT06134986?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.